Gå frakoblet med Player FM -appen!
Immunotherapy series | Assessing PD-L1 status: cytology vs histology in the real world setting
Manage episode 317722619 series 3304844
Histological specimens are recommended to assess a patient’s PD-L1 status; however, it is not always easy or even feasible to secure a histological specimen in advanced cancers such as stage IV NSCLC. Cytological specimens are typically used in this setting to assess other molecular markers such as ALK or ROS1 – should they also be used to assess PD-L1 status?
This episode summarises the evidence for and against a cytological approach, before joining Professor Frederique Penault-Llorca for her opinion on whether cytology should be used to assess PD-L1 status in real-world practice.
References:
Gosney J, et al. Lung Cancer. 2020; 141:101-106
Heymann J, et al. Cancer Cytopathology. 2017; 125(12): 896-907
Wagner C, et al. Eur Respir J. 2018; 52: Suppl. 62, PA2217.
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
32 episoder
Manage episode 317722619 series 3304844
Histological specimens are recommended to assess a patient’s PD-L1 status; however, it is not always easy or even feasible to secure a histological specimen in advanced cancers such as stage IV NSCLC. Cytological specimens are typically used in this setting to assess other molecular markers such as ALK or ROS1 – should they also be used to assess PD-L1 status?
This episode summarises the evidence for and against a cytological approach, before joining Professor Frederique Penault-Llorca for her opinion on whether cytology should be used to assess PD-L1 status in real-world practice.
References:
Gosney J, et al. Lung Cancer. 2020; 141:101-106
Heymann J, et al. Cancer Cytopathology. 2017; 125(12): 896-907
Wagner C, et al. Eur Respir J. 2018; 52: Suppl. 62, PA2217.
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
32 episoder
Alle episoder
×1 Clinical application of next-generation sequencing in advanced thyroid cancer 12:26
1 Adapting thyroid cancer guidelines to local care settings 15:43
1 The ESMO 2022 Clinical Practice Guidelines for use of systemic therapy in advanced thyroid care 15:58
1 Working together in the management of thyroid cancer: An oncologist and endocrinologist in conversation 21:56
1 Treatment decision-making in advanced thyroid cancer with oncogenic alterations 16:24
1 Personalizing care in thyroid cancer using molecular tumor boards 16:52
1 Working together in the management of thyroid cancer: An oncologist and pathologist in conversation 20:57
1 Resistance to RET - Targeted Therapy in Thyroid Cancer 19:22
1 Precision Medicine in Thyroid Cancer Clinical Practice Guidelines 17:40
1 An introduction to precision medicine in Thyroid cancer 17:48
1 Haematology series | ASCO/EHA highlights continued… 17:25
1 Haematology series | ASCO and EHA conference special 25:59
1 Haematology series | What is fitness in acute myeloid leukaemia? 17:55
Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.